Woman measuring blood pressure with digital monitor at home for healthcare routine

(Credit: © Natee Meepian - stock.adobe.com)

In A Nutshell

  • No universal edge: Two major trials found no meaningful cardiovascular advantage from routinely taking daily blood pressure medication at bedtime.
  • One trial stood apart: Spain’s Hygia trial reported a 45% lower relative risk of major cardiovascular events with bedtime dosing, a result that independent trials did not reproduce.
  • Night readings can improve: In a small BedMed subgroup, bedtime dosing lowered blood pressure during sleep, yet the full trial found no drop in heart attacks, strokes or deaths.
  • Consistency matters most: European guidance recommends the most convenient time of day, and U.S. guidance favors once-daily dosing to help people stay on their medication.

Many people who take blood pressure pills have wondered whether the clock matters. Bedtime dosing has an intuitive appeal: blood pressure that stays high during sleep is linked to heart risk, so moving medication closer to bed seems as though it should offer extra protection. But across the largest trials, a better overnight reading has not reliably meant fewer heart attacks, strokes or deaths.

Why Did Blood Pressure Meds At Bedtime Look Better?

Because one large trial appeared to show a huge payoff.

The Hygia Chronotherapy Trial, published online in the European Heart Journal in 2019, assigned 19,084 patients with high blood pressure from Spanish primary care clinics to take their medication either at bedtime or on waking. The trial was randomized, meaning chance decided who got which schedule. It was also open-label: patients and doctors knew the assigned schedule, though the people judging outcomes did not. Over a median 6.3 years, the investigators reported a hazard ratio of 0.55 for major cardiovascular events. In plain terms, the bedtime group had a 45% lower relative risk than the morning group.

An effect that large from simply changing when a pill is taken drew scrutiny. In a 2020 editorial, European Heart Journal editors said they had asked an independent statistician to analyze the data the researchers supplied. That analysis found the published results “consistent to a satisfying degree with the data provided.” The journal said it “could not document any scientific misconduct,” but acknowledged that editors “cannot verify the source data.”

In 2022, a systematic review and consensus statement from the International Society of Hypertension, published in the Journal of Hypertension, examined the published outcome studies of bedtime dosing. It found that all eight “had major methodological and/or other flaws and a high risk of bias in testing the impact of bedtime compared to morning treatment.” In other words, the case for bedtime dosing needed confirmation from independent trials.

Middle-aged woman checks blood pressure monitor and heart rate
Experts say taking your blood pressure with a bare arm is more accurate. (Credit: © amenic181 – stock.adobe.com)

Did Independent Trials Find The Same Benefit?

Not in the strongest independent tests.

The UK-based TIME study, published in The Lancet in 2022, randomized 21,104 adults already being treated for high blood pressure to take their usual medications in the evening or in the morning. Over a median 5.2 years, 3.4% of the evening group and 3.7% of the morning group died of vascular causes or were hospitalized for a heart attack or stroke. The hazard ratio was 0.95, with a 95% confidence interval from 0.83 to 1.10. Because that range includes both a small benefit and a small harm, the result fits with no real difference. Deaths from any cause were also similar.

TIME had limits. Like Hygia, it was open-label. People assigned to evening dosing were more likely to drift from their schedule: 39.0% reported not following it at some point, compared with 22.5% of morning dosers. Participants also needed an email address, 90.5% were White and only about 13% had previous cardiovascular disease. That makes it harder to know how well the results apply to more diverse or higher-risk U.S. patients.

Canada’s BedMed trial, published in JAMA in 2025, randomized 3,357 adults with high blood pressure who were living in the community and treated in primary care. Over a median 4.6 years, bedtime dosing did not reduce the combined rate of death or hospital or emergency visits for stroke, heart attack and related heart emergencies, or heart failure (hazard ratio 0.96).

The researchers had also planned in advance to study a small subgroup of 302 participants who wore monitors that tracked blood pressure over 24 hours. In that subgroup, bedtime dosing lowered systolic blood pressure (the top number) during sleep by an average of 7.4 millimeters of mercury. Nighttime numbers improved, but in the full trial, cardiovascular events did not fall.

The companion BedMed-Frail trial, published in JAMA Network Open in 2025, randomized 776 frail residents of Canadian long-term care facilities, with a median age of 88. Bedtime dosing did not reduce death or major cardiovascular events. It also did not raise rates of falls, fractures, skin ulcers or declines in thinking and behavior.

Does The Body Clock Still Matter?

Yes.

A 2019 American Heart Association scientific statement on measuring blood pressure explains that blood pressure normally falls during sleep, a pattern called “nocturnal dipping,” because activity in the sympathetic nervous system (the body’s “fight or flight” system) declines. Blood pressure then rises quickly when people wake up. The statement notes that heart attacks and strokes frequently occur between 6 a.m. and noon, the same window as that morning rise, though it adds that whether the morning surge itself raises risk is unclear. It also reports that higher blood pressure during sleep is linked to greater cardiovascular risk, even after accounting for daytime readings.

The 2025 European Society of Hypertension position paper adds that hormones such as aldosterone and cortisol, the kidneys’ handling of sodium, and sleep itself all help shape the nightly pattern. It calls nighttime blood pressure “a strong predictor of cardiovascular events.” It also flags obstructive sleep apnea, chronic kidney disease and diabetes as conditions where nighttime readings deserve attention. Yet the same paper describes the bedtime-dosing trials as conflicting and states that “bedtime administration of antihypertensive drugs should not be recommended in routine practice.”

That distinction matters: high nighttime blood pressure can predict risk without proving that routinely moving medication to bedtime lowers that risk.

What’s The Practical Takeaway For Those Who Take High Blood Pressure Medication?

No universal switch, according to current guidance.

The 2024 European Society of Cardiology guideline recommends taking medications “at the most convenient time of day for the patient, to establish a habitual pattern of medication taking to improve adherence.” The 2025 AHA/ACC guideline doesn’t name a best time of day either. It does recommend once-daily dosing over multiple daily doses to help people stay on their medication. It also points to a large trial, TIME, in which adherence was “significantly higher” with morning dosing than with evening dosing. And it notes that there is “no high-quality randomized controlled trial evidence” that lowering blood pressure during sleep reduces cardiovascular risk.

Some patients may still benefit from a tailored schedule. That includes people with documented high nighttime blood pressure, side effects tied to the time of day, a diuretic (“water pill”) that could mean nighttime bathroom trips, or more than one daily dose. Those decisions belong with a clinician, not a switch to flip alone. For most people, the answer to “morning or night?” is simpler: the best time is the one they can stick with every day, as long as the prescribed schedule keeps blood pressure covered around the clock.

Disclaimer: This article is for general information only and is not medical advice. It summarizes large randomized trials, a systematic review, expert position papers and clinical guidelines on when to take blood pressure medication. The trials were run in specific groups of people in Spain, the United Kingdom and Canada, mostly adults already on treatment, so the results may not apply to every patient. People taking blood pressure medication should not change when they take it, how much they take or whether they take it without first talking with a doctor, pharmacist or other qualified health professional. Changing the timing can matter more for certain drugs, for people who take more than one dose a day and for people with conditions such as kidney disease, diabetes or sleep apnea. Anyone with sudden or severe symptoms, such as chest pain, severe headache, trouble speaking or weakness on one side of the body, should seek emergency care right away.



About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor